𝔖 Bobbio Scriptorium
✦   LIBER   ✦

260 Pharmacokinetics and distribution to the brain of (R)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine (H2G) and plasma levels of H2G after dosing a H2G prodrug in the rat: L. Stȧhle1, N. Borg1, N.G. Johansson2, P. Lind2, B. Lindborg2 and B. Öberg2 1Department of Pharmacology, Karolinska Institute, Stockholm, Sweden, 2Medivir AB, Huddinge, Sweden

Book ID
118393329
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
59 KB
Volume
20
Category
Article
ISSN
0166-3542

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

71 SAR studies optimizing HIV-1 inhibiti
71 SAR studies optimizing HIV-1 inhibiting activities of LY73497, a new series of non-nucleoside inhibitors of reverse transcriptase: P. Engelhardt1, M. Hoberg1, J. Kangametsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, L. Vrang1, H. Zhang1, B. Oberg1, N. G. Johansson1, F. W. Bell2, A. S. Cantrell2, J. A. Palkowitz2, S. R. Jaskunas2, C. L. Jordan2, M. D. Kinnick2, J. M. Morin, Jr.2, C. A. Parrish2, P. Pranc2, R. J. Ternansky2, R. T. Vasileff2, and S. J. West2. 1Medivir AB, Huddinge, Sweden; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 62 KB
60 Inhibition of wild type and mutant HI
60 Inhibition of wild type and mutant HIV reverse transcriptases by a new class of non-nucleoside reverse transcriptase inhibitors: H. Zhang1, L. Vrang1, K. Backro2, T. Unge2, P. Engelhardt1, M. Hogberg2, J. Kangasmetsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, N. G. Johansson1, A. S. Cantrell3, S. R. Jaskunas3, J. M. Morin, Jr.3, R. J. Ternansky3, F. W. Bell3, C. L. Jordan3, M. D. Kinnick3, J. A. Palkowitz3, C. A. Parrish3, P. Pranc3, R. T. Vasileff3, S. J. West3, and B. Oberg1. 1Medivir AB, Huddinge, Sweden; 2Department of Molecular Biology, BMC, Uppsala, Sweden; 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 57 KB
44 Combination of LY300082 with AZT and
44 Combination of LY300082 with AZT and DDI give synergistic effects on HIV replication in cells and on HIV reverse transcriptase: H. Zhang1, L. Vrang1, K. Backro2, T. Unge2, P. Engelhardt1, M. Hogberg1, J. Kangasmetsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, N. G. Johansson1, J. M. Morin, Jr.3, R. J. Ternansky3, F. W. Bell3, C. L. Jordan3, M. D. Kinnick3, J. A. Palkowitz3, C. A. Parrish3, P. Pranc3, R. T. Vasileff3, S. J. West3, and B. Oberg1,2. 1Medivir AB, Huddinge, Sweden; Department of Molecular Biology, BMC, Uppsala, Sweden; 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 50 KB
61 Comparative rates of in vitro resista
61 Comparative rates of in vitro resistance development of HIV-1 to new non-nucleoside analog RT inhibitors: L. Vrang1, C. Rydergard1, C. Ahgren1, P. Engelhardt1, M. Hogberg1, N. G. Johansson1, J. Kangasmetsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, A. Karlsson2, C. Lopez3, J. M. Morin, Jr.3, R. J. Ternansky3, F. W. Bell3, C. L. Jordan3, M. D. Kinnick3, J. A. Palkowitz3, C. A. Parrish3, P. Pranc3, R. T. Vasileff3, S. J. West3, and B. Oberg1. 1Medivir AB, Huddinge, Sweden; 2Department of Biochemistry, Stockholm, Sweden; 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 81 KB